Tools

People

Ferran Sanz

  • |alt foto|
    Ferran Sanz
    Head of the Integrative Biomedical Informatics group and Director of GRIB (UPF)
    Extension: 933 160 540

Ferran Sanz is chemical engineer by the Institut Quimic de Sarrià (Barcelona) and BSc and PhD by the Universitat Autònoma de Barcelona. He is Professor of Biostatistics and Biomedical Informatics at Universitat Pompeu Fabra (UPF), scientific staff of the Hospital del Mar Medical Research Institute (IMIM), Head of the Integrative Biomedical Informatics group and Director of GRIB (UPF side).

Author of 150+ articles and supervisor of 20 PhD theses. International coordinator of 10 EU-funded initiatives and a STOA report for the European Parliament. Currently, he is the academic coordinator of an IMI (Innovative Medicines Initiative) project on the in silico prediction of drug toxicity (eTRANSAFE). He is also partner in other ongoing IMI projects (EHDEN, TransQST and FAIRplus), H2020 projects (RISK-HUNT3R, EU-ToxRisk and the ITN Disc4All) and some national funded projects. Chair of the ELIXIR Board, co-president of the Spanish Technology Platform on Innovative Medicines (PTEMI), vice-president of Bioinformatics Barcelona Association (BIB) and founder of the spin off MedBioinformatics Solutions. He was president of the European Federation for Medicinal Chemistry (EFMC) from January 2003 to December 2005, vice-rector for Scientific Policy of the UPF from January 2004 to March 2009 and member of the Scientific Committee of IMI until 2013. He has been visiting professor at the Federico II (Naples), Düsseldorf and Vienna universities, and served as evaluator of scientific projects for the European Commission, the European Science Foundation, the International Human Frontier Science Program and several national scientific agencies (Ireland, Sweden, Italy, Portugal, Czech Republic, Spain, etc.).

Research interests

His research is dedicated to the application of information technologies and computational methods in biomedical research, with a particular focus on the pharmaceutical R&D. His ongoing research lines are:

  • Knowledge management and linked data in the biomedical domain
  • Natural language processing for automatic knowledge extraction from biomedical literature and electronic healthcare records
  • Health-related Real World Data (RWD) analytics
  • Systems biology and network medicine for the study of human diseases and drug safety
  • Integrative knowledge management and exploitation in drug discovery and development

Site Information